Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2020 | 12-2019 | |
| Sales | 812,033 | 412,260 | 306,128 | 294,013 | 298,853 |
| Cost of Goods | 272,865 | 233,478 | 216,818 | N/A | N/A |
| Gross Profit | 539,168 | 178,782 | 89,310 | 294,013 | 298,853 |
| Operating Expenses | 494,920 | 436,382 | 409,679 | 144,722 | 159,236 |
| Operating Income | 45,113 | -257,122 | -319,551 | 149,291 | 139,617 |
| Interest Expense | 56,853 | 50,025 | 31,610 | 61,565 | 79,174 |
| Other Income | -56,348 | 25,257 | 9,746 | -5,484 | -313 |
| Pre-tax Income | -68,088 | -281,890 | -341,415 | 82,242 | 60,130 |
| Income Tax | N/A | N/A | N/A | 1,800 | 4,783 |
| Net Income Continuous | -68,088 | -281,890 | -341,415 | 80,442 | 55,347 |
| Net Income Discontinuous | N/A | N/A | N/A | -52,709 | -24,336 |
| Net Income | $-68,088 | $-281,890 | $-341,415 | $27,733 | $31,011 |
| EPS Basic Total Ops | -3.22 | -10.66 | -13.24 | 1.08 | 1.25 |
| EPS Basic Continuous Ops | -0.41 | -7.94 | -9.77 | 4.08 | 2.62 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | -3.00 | -1.37 |
| EPS Diluted Total Ops | -3.22 | -10.66 | -13.24 | 1.06 | 1.23 |
| EPS Diluted Continuous Ops | -0.41 | -7.94 | -9.77 | 4.03 | 2.58 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | -2.97 | -1.35 |
| EPS Diluted Before Non-Recurring Items | -0.33 | N/A | N/A | 5.06 | 2.34 |
| EBITDA(a) | $80,496 | $-201,155 | $-265,172 | $269,381 | $255,665 |